Emmaus Life Sciences, Inc. is a biopharmaceutical company. The Company is engaged in discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. The most common occurring in more than 10% of patients treated with Endari were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain. Its solution provides a safe and effective means for reducing the frequency of sickle cell crises in patients with SCD.